Bristol-Myers Squibb Company (BMY)
NYSE · Price as of · Delayed Quote
- Analysts24
- Implied upside+6.4%
- Target range$41.00 to $82.00
- EPS expected$1.25 -23%
- A year ago$1.63
- Revenue expected$12.73B +4.1%
- Estimate range$0.98 to $1.75
- Priced move±5.5%
How Congress has done in BMY
Every purchase of BMY disclosed by a member of Congress in the last 5 years, scored over the 12 months after the trade date against SPY over the same window.
| Measure | BMY | SPY |
|---|---|---|
| Median 12-month return after purchase | -8.7% | +28.6% |
| Median difference vs SPY | -37.6% | — |
| Purchases that beat SPY | 0 of 5 (0%) | — |
| Members who bought | 5 | — |
Most frequent buyers: Daniel Goldman (1), Greg Stanton (1), Julie Johnson (1), Tommy Tuberville (1), Virginia Foxx (1).
These are not returns anyone actually earned. Disclosures report a dollar bracket and no share count, so every purchase is counted once and weighted equally, and sales are not matched back to the buys that opened them. 1 of the 5 purchases are disclosed as a spouse's or dependent's rather than the member's own. Purchases from the last 12 months are excluded because their window has not closed yet.
Congress trades in BMY
| Date | Member | Action | Amount | |
|---|---|---|---|---|
| 2025-04-15 | Tommy Tuberville AL | Sale | $1,001 - $15,000 |
SEC filings
Bristol-Myers Squibb news
Frequently asked questions
When does BMY report earnings?
Bristol-Myers Squibb Company (BMY) is scheduled to report quarterly results on October 29, 2026, before the open. The 23-analyst consensus is $1.25 per share on revenue of $12.73B for the quarter ended September 30, 2026, against $1.63 and $12.22B a year earlier. It has beaten the consensus EPS estimate in all four of the last four quarters. The options market is pricing a move of about 5.5% in either direction on the report, based on the cost of the at-the-money straddle expiring October 30, 2026.
What do analysts expect for BMY?
24 analysts cover Bristol-Myers Squibb Company (BMY). The consensus rating is Buy. The average price target is $65.42, in a range of $41.00 to $82.00.
Are insiders buying or selling BMY?
We have no qualifying Form 4 insider purchases or sales on record for Bristol-Myers Squibb Company (BMY). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Has Congress made money trading BMY?
5 members of Congress have disclosed buying BMY in the last 5 years, 5 purchases in total. Measured over the 12 months after each trade date, the median purchase returned -8.7% against +28.6% for SPY over the same windows, and 0 of the 5 (0%) beat the index. These are not returns anyone actually earned: congressional disclosures report a dollar bracket and no share count, so each purchase is counted once and weighted equally, and later sales are not matched back to the buys that opened them.
Where can I see BMY SEC filings?
We could not resolve current EDGAR filings for BMY. This usually means the ticker is a foreign or over-the-counter listing that does not file with the SEC.